

Appendix 2 (as supplied by authors):

Table 1: Healthcare Utilization at Baseline; Women not taking Combined Oral Contraceptives		
	PCOS*	Matched Controls
Number of Women	28,820	115,152
Mean age, yr	30.4	30.4
Healthcare Utilization‡		
Hospitalization, %	8.70	10.03
ER Visit, %	10.51	11.07
Office Visit, %	59.54	59.91
* PCOS defined as a claim for PCOS (ICD-9-CM 256.4)		

Table 2: Comparison of Medication Use and Comorbidities at Cohort Entry and Cohort End; Women not taking Combined Oral Contraceptives

	Population Characteristics at Cohort Entry		Population Characteristics at Cohort End	
	PCOS*	Matched Controls	PCOS†	Matched Controls
Medications, %				
ACEI / ARB	2.13	2.27	4.71	4.37
Beta Blocker	2.90	2.83	6.39	5.53
Benzodiazepine	6.55	7.06	15.77	15.67
Calcium Channel	1.05	1.04	2.48	2.16
Diabetes Meds	14.38	14.31	26.90	15.43
SSRI/TCA	11.37	11.47	20.94	21.39
Statin/Fibrate	1.96	2.10	5.29	4.38
Comorbidities, %				
Acne	7.64	7.86	17.40	15.23
Asthma	6.67	6.55	13.98	12.37
COPD	3.88	4.14	10.38	9.84
Diabetes	7.61	7.48	17.59	10.43
Dysmenorrhea	4.79	4.88	11.92	9.25
Endometriosis	3.31	3.34	8.00	5.58
Hyperlipidemia	11.91	12.02	27.92	21.24
Hypertension	10.31	10.56	21.23	17.35
Hypothyroid	9.20	9.56	17.90	14.33
Ovarian Inflammation	2.72	2.75	6.93	4.95
Vaginal Inflammation	11.44	12.35	26.39	25.50
Uterine Leiomyoma	2.41	2.62	6.96	5.93
Menstrual Irregular	41.91	42.43	71.44	53.77
Migraine	5.63	5.73	12.90	12.06
Mood / Anxiety Dis.	14.66	15.47	29.76	28.79
Obesity	14.99	15.72	33.34	22.18
PUD	0.35	0.41	1.19	1.20
PTS (PMS/PMDD)	0.99	1.02	3.22	2.38
Sleep Disorder	0.82	0.81	3.88	2.31
Smoking	3.06	3.23	8.00	8.97

* PCOS defined as a claim for PCOS (ICD-9-CM 256.4)